Table 4.
Univariate and multivariate analyses of overall survival (OS) in the 52 pNEN patients included in this study.
| OS in pNEN | univariate analysis | multivariate analysis | ||
|---|---|---|---|---|
| variables | HR (95% CI) | p value | HR (95% CI) | p value |
| Age (60<) | 4.396 (0.023–84.120) | 0.082 | ||
| Sex (male) | 1.239 (0.207–7.407) | 0.814 | ||
| Lymph node metastasis | 2.904 (0.484–17.416) | 0.222 | ||
| WHO Grade (G1, 2/G3, NEC) | 9.482 (1.496–60.092) | 0.004 | 5.505 (0.745–40.677) | 0.095 |
| ENETS Stage (I, IIA/IIB-IV) | 5.207 (0.581–46.626) | 0.099 | ||
| CD3+/PD-1 high | 3.458 (1.223–9.776) | 0.013 | 3.220 (0.291–35.609) | 0.340 |
| CD3+/PD-L1 high | 5.337 (0.593–48.035) | 0.095 | ||
The univariate analysis for age, sex, lymph node metastasis, WHO grade, ENETS stage, and for the immune profiles was performed using the log-rank test. The multivariate analysis was performed using the Cox proportional hazards model.